COMMUNIQUÉS West-GlobeNewswire
-
IMUNON to Present at the Life Sciences Investor Forum on June 25th
22/06/2026 -
NADP and AADOM announce partnership
22/06/2026 -
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
22/06/2026 -
iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant
22/06/2026 -
Zealand Pharma - Transactions related to share buy-back program (week 25, 2026)
22/06/2026 -
Ozari Health Releases 2026 Online GLP-1 Provider Checklist
22/06/2026 -
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 25 - 2026
22/06/2026 -
Genista Launches Refreshed Brand and Website, Positioning Itself as the Operating System for Product Safety
22/06/2026 -
IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2026
22/06/2026 -
Cosmos Health Builds Contract Manufacturing Orderbook to Over 25 Million Units; Division Positioned to Generate Over $10 Million in Recurring Annual Profit
22/06/2026 -
Hyperion DeFi and Blockdaemon Partner to Expand Institutional Hyperliquid Staking Infrastructure
22/06/2026 -
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
22/06/2026 -
Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.
22/06/2026 -
Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
22/06/2026 -
Autonomix Medical Announces Standalone Neural Sensing Program with Evidence of Real-Time Renal Nerve Activity Change
22/06/2026 -
InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds
22/06/2026 -
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
22/06/2026 -
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion
22/06/2026 -
Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum
22/06/2026
Pages